Oruka Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Oruka Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.00
Cost of Revenue0.030.000.000.000.000.000.00
Gross Profit-0.030.000.000.000.000.000.00
Operating Expenses
Research & Development75.061.014.7513.834.991.834.24
Selling, General & Administrative13.046.285.855.504.773.983.88
Operating Expenses88.107.3010.6019.349.775.818.12
Operating Income-88.12-7.30-10.60-19.34-9.77-5.81-8.12
Other Income/Expense
Interest Income5.860.000.000.000.000.000.16
Interest Expense1.470.000.000.000.000.000.01
Other Income/Expense4.400.000.000.000.000.000.00
Income
Income Before Tax-83.72-5.34-9.93-19.32-9.75-5.65-7.96
Income Tax Expense0.00-0.19-0.36-0.70-0.01-0.17-0.03
Net Income-83.72-5.34-9.93-19.32-9.74-5.48-7.93
Net Income - Continuous Operations-83.720.000.000.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-82.23-5.42-10.48-19.24-9.65-5.55-7.93
EBIT-95.26-5.53-10.60-19.34-9.74-5.64-7.96
Depreciation & Amortization0.030.020.020.020.01-0.020.00
Earnings Per Share
Basic EPS-5.00--8.00-17.00-25.00--10.00
Diluted EPS-5.00--8.00-17.00-25.00-50.00-10.00
Basic Shares Outstanding16.7914.421.201.160.390.110.77
Diluted Shares Outstanding16.7914.421.201.160.390.110.77